Al's Comment:

 Unfortunately this trial failed to show any survival benefit.  We had high hopes for this drug Veliparib, which is a PARP inhibitor that does cross the blood brain barrier.   We need better treatments for a glioblastoma with unmethylated MGMT as the overall survival for both the experimental and treatment group was less than 13 months.  We are still hoping that the experimental treatment Val-083 which is also in trials for unmethylated Glioblastoma shows better results.

Posted on: 06/14/2021

Veliparib + RT + TMZ in Patients With Unmethylated MGMT Glioblastoma


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
HERE to read it!